Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.33 |
| ▸ | CHRNA5 | P30532 | 1/20 | 0.33 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.33 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3008935 | 1.00 | KDM4E (0.38) | KDM4ENPC1CYP1A2CYP2D6HPGD | |
| SCHEMBL10326343 | 0.92 | TACR1 (0.37) | KDM4ENPC1CYP1A2CYP2D6HPGD | |
| SCHEMBL15281108 | 0.91 | TACR1 (0.38) | KDM4ENPC1CYP1A2CYP2D6HPGD | |
| SCHEMBL15248772 | 0.91 | TACR1 (0.38) | KDM4ENPC1CYP1A2CYP2D6HPGD | |
| SCHEMBL14365129 | 0.91 | TACR1 (0.38) | KDM4ENPC1CYP1A2CYP2D6HPGD | |
| SCHEMBL10326849 | 0.86 | KDM4E (0.43) | KDM4ENPC1CYP1A2CYP2D6HPGD | |
| SCHEMBL10326340 | 0.85 | CYP1A2 (0.41) | KDM4ENPC1CYP1A2CYP2D6HPGD | |
| SCHEMBL3006875 | 0.84 | TACR1 (0.41) | KDM4ENPC1CYP1A2CYP2D6HPGD | |
| SCHEMBL1262080 | 0.84 | TACR1 (0.41) | KDM4ENPC1CYP1A2CYP2D6HPGD | |
| SCHEMBL1262083 | 0.84 | TACR1 (0.41) | KDM4ENPC1CYP1A2CYP2D6HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070276142-A1 | Catalytic Asymmetric Synthesis of Optically Active Alpha-Halo-Carbonyl Compounds | CHEMINOVA A/S (DK) | 2007-11-29 | — | — | US | disclosed |
| US-20070276142-A1 | Catalytic Asymmetric Synthesis of Optically Active Alpha-Halo-Carbonyl Compounds | CHEMINOVA A/S (DK) | 2007-11-29 | — | — | US | disclosed |
| US-20070276142-A1 | Catalytic Asymmetric Synthesis of Optically Active Alpha-Halo-Carbonyl Compounds | CHEMINOVA A/S (DK) | 2007-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070276142-A1 | Catalytic Asymmetric Synthesis of Optically Active Alpha-Halo-Carbonyl Compounds | CBR1, CBR3, HAO1 | KDM4E 3878/4885NPC1 1457/4885CYP1A2 55/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.